All data are based on the daily closing price as of April 1, 2025
s

SCI Pharmtech

4119.TW
2.45 USD
-0.05
-2.00%

Overview

Last close
2.45 usd
Market cap
292.28M usd
52 week high
3.23 usd
52 week low
2.45 usd
Target price
2.71 usd

Valuation

P/E
18.1614
Forward P/E
N/A
Price/Sales
6.3529
Price/Book Value
1.7674
Enterprise Value
300.63M usd
EV/Revenue
6.5483
EV/EBITDA
11.2593

Key financials

Revenue TTM
45.91M usd
Gross Profit TTM
12.37M usd
EBITDA TTM
12.95M usd
Earnings per Share
0.13 usd
Dividend
N/A usd
Total assets
219.62M usd
Net debt
12.17M usd

About

SCI Pharmtech, Inc., together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, and valproic acid; and develops benserazide, CBN, and CBD. It also provides intermediate products, such as diethyl isobutyl malonate, benzhydrylamine, 1-Benzhydrylazetidin-3-ol, azetidin-3-ol hydrogenchloride, 1-(2-hydroxyphenyl)-3-phenylpropan-1-one, ritalinic acid, d-ritalinic acid HCl, pyrogallol aldehyde, menthadienol, 5-pentylbenzene-1,3-diol olivetol, methyl 2,4-dihydroxy-6-pentylbenzoate, ethyl 2,4-dihydroxy-6-pentylbenzoate ethyl olivetolate, divarinol, lisdexamfetamine intermediate, UDP-GIcNAz, and UDP-GaINAz. In addition, the company offers customized production services. The company was incorporated in 1987 and is based in Taoyuan City, Taiwan.
  • Symbol
    4119.TW
  • Exchange
    TW
  • Isin
    TW0004119003
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
  • Headquarter
    Taoyuan City
  • Web site
    https://www.sci-pharmtech.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top